Prospective, Multicentre, Non-interventional (Observational) Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer.
- Male patients for whom hormone treatment for advanced prostate cancer is indicated
- Age > 18 years.
- Documented elevated PSA levels.
Contraindications for Vantas® (in accordance with Summary of Product Characteristics
Type of Study:
Observational Model: Case-Only, Time Perspective: Prospective
Treatment duration follow-up for each patient.
Outcome Time Frame:
Thomas Björk, MD
Urology Dep. Skane University Hospital, Malmoe, Sweden
Sweden: Regional Ethical Review Board
THE VANTAS STUDY
- Prostate Cancer
- Prostatic Neoplasms